Raloxifene improves cognition in schizophrenia: Spurious result or valid effect?

Frontiers in Psychiatry

Volumn 8, Issue OCT, 2017, Pages

  Weickert, Thomas W ^a,b   Weickert, Cynthia Shannon ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Cognition; Raloxifene; Schizophrenia; Selective estrogen receptor modulator; Symptom severity

Indexed keywords

RALOXIFENE;

ATTENTION DISTURBANCE; BRAIN CORTEX; BRAIN FUNCTION; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EXECUTIVE FUNCTION; FUNCTIONAL DISEASE; HIPPOCAMPUS; HUMAN; LOW DRUG DOSE; MEMORY DISORDER; MENTAL CAPACITY; MENTAL TASK; MENTAL TEST; NOTE; PSYCHOSIS; SCHIZOPHRENIA; SOCIAL DISABILITY; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; VERBAL MEMORY; WORKING MEMORY;

EID: 85032735934     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2017.00202     Document Type: Note

References (10)

1. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol (2014) 24:223-31. doi:10.1016/j.euroneuro.2013.11.012
2. Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry (2015) 20:685-94. doi:10.1038/mp.2015.11
3. Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry (2016) 73:947-54. doi:10.1001/jamapsychiatry.2016.1383
4. Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, et al. Raloxifene plus antipsychotics versus placebo plus antipsychotics in severely ill decompensated postmenopausal women with schizophrenia or schizoaffective disorder: a randomized control trial. J Clin Psychiatry (2017) 78:e758-65. doi:10.4088/JCP.15m10498
5. Kindler J, Weickert CS, Skilleter AJ, Catts SV, Lenroot R, Weickert TW. Selective estrogen receptor modulation increases hippocampal activity during probabilistic association learning in schizophrenia. Neuropsychopharmacology (2015) 40:2388-97. doi:10.1038/npp.2015.88
6. Ji E, Weickert CS, Lenroot R, Kindler J, Skilleter AJ, Vercammen A, et al. Adjunctive selective estrogen receptor modulator increases neural activity in the hippocampus and inferior frontal gyrus during emotional face recognition in schizophrenia. Transl Psychiatry (2016) 6:e795. doi:10.1038/tp.2016.59
7. Kindler J, Weickert CS, Schofield PR, Lenroot R, Weickert TW. Raloxifene increases prefrontal activity during emotional inhibition in schizophrenia based on estrogen receptor genotype. Eur Neuropsychopharmacol (2016) 26:1930-40. doi:10.1016/j.euroneuro.2016.10.009
8. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity and comparison with a standard cognitive battery. Schizophr Res (2004) 68:283-97. doi:10.1016/j.schres.2003.09.011
9. Martin DW. Doing Psychology Experiments. 7th ed. Belmont, CA: Thompson/Wadsworth (2008).
10. Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry (2015) 72:14-21. doi:10.1001/jamapsychiatry.2014.2127